

## **Interleukin-6 in COVID-19: A Systematic Review and Meta-Analysis**

Supplementary Appendix

**Authors:** Eric A. Coomes, M.D.; Hourmazd Haghbayan, M.D., M.Sc., FRCPC

## **SUPPLEMENTARY APPENDIX**

### **Table of Contents**

**S1. Search Strategy**

**S2. Cytokine and Inflammatory Markers, other than IL-6**

**S3. Risk of Bias Assessment via the Quality in Prognostic Studies (QUIPS) Tool of Included Cohort Studies Relating IL-6 Levels with Disease Severity**

**S4. Supplemental References**

## S1. Search Strategy

Ovid MEDLINE and EMBASE

1. (severe acute respiratory syndrome OR SARS OR SARS-CoV OR SARS CoV OR novel coronavirus OR nCoV OR 2019-nCoV OR COVID OR SARS-CoV-2 OR COVID-19 OR Wuhan).ti,ab,kf,kw. OR exp severe acute respiratory syndrome coronavirus 2/
2. (tocilizumab OR toculizumab OR atlizumab OR actemra OR siltuximab OR sarilumab OR kevezara).ti,ab,kf,kw. OR exp tocilizumab/ OR exp siltuximab/ OR exp sarilumab/
3. (IL-6 OR cytokine OR interleukin OR macrophage activation syndrome OR hemophagocytic lymphohistiocytosis OR HLH).ti,ab,kf,kw. OR exp Cytokines/ OR exp cytokine/ OR exp Interleukins/ OR exp Interleukin-6/ OR exp interleukin 6/ OR exp Receptors, Interleukin-6/ OR exp Macrophage Activation Syndrome/ OR exp Lymphohistiocytosis, Hemophagocytic/ OR exp hemophagocytic syndrome/
4. #1 AND (#2 OR #3)
5. limit 5 to yr="2019 -Current"

Ovid MEDLINE and EMBASE

1. (novel coronavirus OR nCoV OR 2019-nCoV OR COVID OR SARS-CoV-2 OR COVID-19 OR Wuhan).ti,ab,kf,kw. OR exp severe acute respiratory syndrome coronavirus 2/
2. limit 5 to yr="2020 -Current"

MedRXiv, BioRXiv, ChinaRXiv:

"tocilizumab" w/ date limit 2019/01/01 - 2020/03/15

Google Scholar:

("severe acute respiratory syndrome" OR "SARS" or "SARS-CoV" or "SARS CoV" or "nCoV" or "2019-nCoV" or "COVID" or "SARS-CoV-2" or "COVID-19") AND ("tocilizumab") w/ date limit 2019/01/01 - 2020/03/15

## **S2. Cytokine and Inflammatory Markers, other than IL-6**

Beyond IL-6, several other cytokines, inflammatory markers, and acute phase reactants were associated with disease severity and clinical outcomes. In a landmark early cohort on COVID-19 in Wuhan, Huang et al.,<sup>1</sup> cytokine levels were higher amongst COVID-19 patients requiring ICU care compared to healthy controls for IL-6 (median 6.1 pg/mL, IQR 1.8-37.7 versus 0 pg/mL, IQR 0-0; p=0.003). IL-2 levels were significantly higher in patients requiring ICU compared to those not requiring ICU admission (median 8.6 pg/mL, IQR 7.6-12.7 versus median 6.3 pg/mL, IQR 4.3-9.9; p=0.043)

Diao et al.<sup>2</sup> identified elevated IL-6, TNF- $\alpha$ , and IL-10 levels across patients with COVID-19, with significantly higher levels amongst patients required ICU admission.

Chen et al.<sup>3</sup> identified a gradient of IL-6 and IL-2 receptor (IL-2R) levels elevations with increasing severity of COVID-19 disease; levels of both significantly increased from mild disease (soluble IL-2R:  $631 \pm 37$  U/mL; IL-6:  $34 \pm 7$  pg/mL), to severe disease (sIL-2R:  $902 \pm 51$  U/mL; IL-6:  $52 \pm 11$  pg/mL), to critically ill (sIL-2R:  $1185 \pm 80$  U/mL; IL-6:  $108 \pm 12$  pg/mL). In contrast, levels of IL-1 $\beta$ , IL-8, IL-10, and TNF- $\alpha$  were not significantly different across the spectrum of disease severity.


Qin et al.<sup>4</sup> similarly identified that severe cases have significantly elevated levels of serum inflammatory biomarkers compared with non-severe cases, including IL-6 (25.2 pg/mL versus 13.3 pg/mL; p<0.001), IL-2R (757 U/mL versus 663.5 U/mL; p=0.001), and ferritin (800.4 mcg/L versus 523.7 mcg/L; p<0.001). Additional elevations were identified amongst severe cases for TNF- $\alpha$  (8.7 pg/mL versus 8.4 pg/mL; p=0.037), IL-10 (6.6 pg/mL versus 5.0 pg/mL; p<0.001), and CRP (57.9 mg/L versus 33.2 mg/L; p<0.001).

Liu et al.<sup>5</sup> identified significantly increased levels of IL-6 amongst severe cases (median 36.5, IQR 30.8-42 versus median 2.4, IQR 2.1-2.9; p=0.016). Patients with severe disease also had elevations of ferritin, ESR, and CRP. Baseline levels of IL-2, IL-4, IL-10, TNF- $\alpha$ , and IFN- $\gamma$  were within the normal range.

In the analysis of risk factors for ARDS and death by Wu et al.,<sup>6</sup> patients with COVID-19 who progressed to ARDS had significantly increased IL-6 (median 7.39 pg/mL, IQR 5.63-10.89 versus median 6.29 pg/mL, IQR 5.36-7.83; p=0.03) and ferritin (median 1029.28 mcg/L, IQR 546.26->2000 versus median 457.66 mcg/L, IQR 223.73-702.65; p<0.001). Further, elevated IL-6 was associated with death. Similarly, Ruan et al.<sup>7</sup> identified significantly higher IL-6 levels amongst patients who die from COVID-19 compared to those who survive (11.4 $\pm$ 8.5 pg/mL versus 6.8 $\pm$ 3.6 pg/mL, p<0.001).

### S3.

**Supplementary Figure 1.** Risk of Bias Assessment via the Quality in Prognostic Studies (QUIPS) Tool of Included Cohort Studies Relating IL-6 Levels with Disease Severity



#### **S4. SUPPLEMENTARY REFERENCES**

1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in wuhan, china. *Lancet*. 2020;395(10223):497-506.
2. Diao. **Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19).** .
3. Chen L, Liu HG, Liu W, et al. Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. *Zhonghua Jie He He Hu Xi Za Zhi*. 2020;43(0):E005.
4. Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in wuhan, china. *Clin Infect Dis*. 2020.
5. Liu. **The potential role of IL-6 in monitoring severe case of coronavirus disease 2019.** .
6. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in wuhan, china. *JAMA Intern Med*. 2020.
7. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from wuhan, china. *Intensive Care Med*. 2020.